Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prognostic Value of Vascular Endothelial Growth Factor Expression in Resected Gastric Cancer

  • Liu, Lei (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University) ;
  • Ma, Xue-Lei (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University) ;
  • Xiao, Zhi-Lan (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University) ;
  • Li, Mei (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University) ;
  • Cheng, Si-Hang (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University) ;
  • Wei, Yu-Quan (State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University)
  • Published : 2012.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background and Aims: Vascular endothelial growth factor (VEGF) is a potential prognostic biomarker for patients with resected gastric cancer. However, its role remains controversial. The objective of this study was to conduct a systematic review and meta-analysis of published literature. Methods: Relevant literature was identified using Medline and survival data from published studies were collected following a methodological assessment. Quality assessment of eligible studies and meta-analysis of hazard ratio (HR) were performed to review the correlation of VEGF overexpression with survival and recurrence in patients with gastric cancer. Results: Our meta-analysis included 44 published studies with 4,794 resected patients. VEGF subtype for the prediction of overall survival (OS) included tissue VEGF (HR=2.13, 95% CI 1.71-2.65), circulating VEGF (HR=4.22, 95% CI 2.47-7.18), tissue VEGF-C (HR=2.21, 95% CI 1.58-3.09), tissue VEGF-D (HR=1.73, 95% CI 1.25-2.40). Subgroup analysis showed that HRs of tissue VEGF for OS were, 1.78 (95% CI 0.90-3.51) and 2.31 (95% CI 1.82-2.93) in non-Asians and Asians, respectively. The meta-analysis was also conducted for disease free survival (DFS) and disease specific survival (DSS). Conclusion: Positive expression of tissue VEGF, circulating VEGF, VEGF-C and VEGF-D were all associated with poor prognosis in resected gastric cancer. However, VEGF demonstrated no significant prognostic value for non-Asian populations. Circulating VEGF may be better than tissue VEGF in predicting prognosis.

Keywords

References

  1. Akdogan R, Aydin F, Ozdemir F, et al (2006). The effects of VEGF and VEGFR-2 on survival in patients with gastric cancer. J Exp Clin Cancer Res, 25, 83-8.
  2. Altman DG, Deeks JJ, Higgins JP, Thompson SG (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
  3. Altman DG, McShane LM, Sauerbrei W, et al (2006). Reporting recommendations for tumor marker prognostic studies (remark). Exp Oncol, 28, 99-105.
  4. Amaya H, Matsumura M, Shimomatsuya T, Tanigawa N (1997). Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J Clin Oncol, 15, 826-32.
  5. Aoyagi K, Kouhuji K, Yano S, et al (2005). VEGF significance in peritoneal recurrence from gastric cancer. Gastric Cancer, 8, 155-63. https://doi.org/10.1007/s10120-005-0329-4
  6. Bai M, Goussia A, Skarlos DV, et al (2007). Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group. Anticancer Res, 27, 2973-83.
  7. Bates DO, Hillman NJ, Neal CR, Pocock TM, Williams B (2002). Regulation of microvascular permeability by vascular endothelial growth factors. J Anat, 200, 581-97. https://doi.org/10.1046/j.1469-7580.2002.00066.x
  8. Bazas VM, Demash DV, Galakhin KO, Lukyanova NY, Myasoedov DV (2008). Relation between cell-to-cell adhesion and angiogenesis and clinico-morphological prognostic factors in patients with gastric cancer. Exp Oncol, 30, 235-9.
  9. Berse B, Brown LF, Van de Water L, et al (1992). Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell, 3, 211-20. https://doi.org/10.1091/mbc.3.2.211
  10. Bray F, Center MM, Jemal A, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
  11. Burdett S, Ghersi D, Stewart LA, Sydes MR, Tierney JF (2007). Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 8, 16. https://doi.org/10.1186/1745-6215-8-16
  12. Cao W, Mo M, Wang X, et al (2010). VEGF and cortactin expression are independent predictors of tumor recurrence following curative resection of gastric cancer. J Surg Oncol, 102, 325-30. https://doi.org/10.1002/jso.21644
  13. Chen J, Li T, Wu Y, et al (2011). Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis. J Cancer Res Clin Oncol, 137, 1799-812. https://doi.org/10.1007/s00432-011-1057-2
  14. Chen XC, Gou HF, Zhu J, et al (2011). Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res, 30, 14. https://doi.org/10.1186/1756-9966-30-14
  15. Chen XC, Gou HF, Zhu J, et al (2011). Expressions of COX-2 and VEGF-C in gastric cancer: correlations with lymphangiogenesis and prognostic implications. J Exp Clin Cancer Res, 30, 14. https://doi.org/10.3346/jkms.2008.23.4.592
  16. Choi JH, Oh YH, Park YW, et al (2008). Correlation of vascular endothelial growth factor-D expression and VEGFR-3-positive vessel density with lymph node metastasis in gastric carcinoma. J Korean Med Sci, 23, 592-7. https://doi.org/10.3346/jkms.2008.23.4.592
  17. Clark JW, Duda DG, Jain RK, Loeffler JS (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol, 3, 24-40. https://doi.org/10.1158/1078-0432.CCR-04-1870
  18. Cunha IW, Ioannidis JP, Kyzas PA (2005). Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res, 11, 1434-40. https://doi.org/10.1158/1078-0432.CCR-04-1870
  19. Da MX, Wang J, Wu XT, et al (2008). Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res, 39, 92-9. https://doi.org/10.1016/j.arcmed.2007.06.021
  20. Deguchi K, Ichikawa D, Soga K, et al (2010). Clinical significance of vascular endothelial growth factors C and D and chemokine receptor CCR7 in gastric cancer. Anticancer Res, 30, 2361-6. https://doi.org/10.1016/j.surg.2009.04.025
  21. Deguchi K, Ichikawa D, Soga K, et al (2010). Clinical significance of vascular endothelial growth factors C and D and chemokine receptor CCR7 in gastric cancer. Anticancer Res, 30, 2361-6.
  22. Deng J, Liang H, Sun D, et al (2009). Vascular endothelial growth factor-D is correlated with hepatic metastasis from gastric cancer after radical gastrectomy. Surgery, 146, 896-905. https://doi.org/10.1016/j.surg.2009.04.025
  23. Deng MH, Dong WG, Qiu WS, Wang TB (2007). Association of serum vascular endothelial growth factor-C and lymphatic vessel density with lymph node metastasis and prognosis of patients with gastric cancer. World J Gastroenterol, 13, 1794-8. https://doi.org/10.3748/wjg.v13.i12.1794
  24. Detmar M, Wissmann C (2006). Pathways targeting tumor lymphangiogenesis. Clin Cancer Res, 12, 6865-8. https://doi.org/10.1158/1078-0432.CCR-06-1800
  25. Detmar M, Wissmann C (2006). Pathways targeting tumor lymphangiogenesis. Clin Cancer Res, 12, 6865-8. https://doi.org/10.1002/bjs.6780
  26. Ding S, Li C, Lin S, et al (2007). Distinct roles of VEGF-A and VEGF-C in tumour metastasis of gastric carcinoma. Oncol Rep, 17, 369-75.
  27. Ding S, Li C, Lin S, et al (2007). Distinct roles of VEGF-A and VEGF-C in tumour metastasis of gastric carcinoma. Oncol Rep, 17, 369-75.
  28. Doki Y, Fujiwara Y, Urano N, et al (2006). Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma. Gastric Cancer, 9, 44-9. https://doi.org/10.1007/s10120-005-0356-1
  29. Elizalde I, Metges JP, Vidal O, et al (2009). High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. Br J Surg, 96, 1443-51. https://doi.org/10.1002/bjs.6780
  30. Endo Y, Fujita H, Yonemura Y, et al (1999). Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin Cancer Res, 5, 1823-9. https://doi.org/10.1245/s10434-007-9596-0
  31. Feldman AL, Paciotti GF, Tamarkin L, et al (2000). Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res, 6, 4628-34. https://doi.org/10.1038/sj.bjc.6601455
  32. Ferrara N, Gerber HP, Hillan KJ, Novotny W (2004). Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov, 3, 391-400. https://doi.org/10.1038/nrd1381
  33. Ferrara N, Houck K, Jakeman L, Leung DW (1992). Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev, 13, 18-32. https://doi.org/10.1007/s10147-005-0528-3
  34. Ferraraccio F, Lieto E, Orditura M, et al (2008). Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol, 15, 69-79. https://doi.org/10.1245/s10434-007-9596-0
  35. Fondevila C, Fuster J, Metges JP, et al (2004). p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer, 90, 206-15. https://doi.org/10.1038/sj.bjc.6601455
  36. Fujioka S, Ishibashi Y, Shida A, et al (2005). Prognostic significance of vascular endothelial growth factor D in gastric carcinoma. World J Surg, 29, 1600-7. https://doi.org/10.1007/s00268-005-0076-z
  37. Fujioka S, Kobayashi K, Shida A, et al (2006). Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma. Int J Clin Oncol, 11, 38-43. https://doi.org/10.1007/s10147-005-0528-3
  38. Fujisaki K, Matsuo K, Mitsuyama K, Tanikawa K, Toyonaga A (1998). Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol, 93, 249-52. https://doi.org/10.1111/j.1572-0241.1998.00249.x
  39. Ghaneh P, Neoptolemos JP, Smith RA, Tang J, Tudur-Smith C (2011). Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer, 104, 1440-51. https://doi.org/10.1038/bjc.2011.110
  40. Ghaneh P, Neoptolemos JP, Smith RA, Tang J, Tudur-Smith C (2011). Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer, 104, 1440-51. https://doi.org/10.1002/sim.1303
  41. Gores GJ, Kurtz DM, Roberts LR, Schoenleber SJ, Talwalkar JA (2009). Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer, 100, 1385-92. https://doi.org/10.1038/sj.bjc.6605017
  42. Han FH, He YL, Li HM, Zhan WH, Zheng DH (2010). The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol, 36, 1172-9. https://doi.org/10.1016/j.ejso.2010.09.002
  43. Han FH, He YL, Li HM, Zhan WH, Zheng DH (2010). The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol, 36, 1172-9. https://doi.org/10.1007/s004230050202
  44. Hattori N, Kido S, Kitadai Y, et al (2001). Interleukin 8 and vascular endothelial growth factor -- prognostic factors in human gastric carcinomas. Eur J Cancer, 37, 1482-7. https://doi.org/10.1016/S0959-8049(01)00147-2
  45. Hu NZ, Shi H, Xie HJ, Xu JM (2003). Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol, 9, 1421-6. https://doi.org/10.1002/(SICI)1097-0215(19980417)79:2<144::AID-IJC8>3.0.CO;2-T
  46. Hutton JL, Marson AG, Smith CT, Williamson PR (2002). Aggregate data meta-analysis with time-to-event outcomes. Stat Med, 21, 3337-51. https://doi.org/10.1002/sim.1303
  47. Ichikura T, Mochizuki H, Ohkura E, Tomimatsu S (2001). Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J Surg Oncol, 78, 132-7. https://doi.org/10.1002/jso.1133
  48. Iida S, Kolev Y, Uetake H, et al (2007). Prognostic significance of VEGF expression in correlation with COX-2, microvessel density, and clinicopathological characteristics in human gastric carcinoma. Ann Surg Oncol, 14, 2738-47. https://doi.org/10.1245/s10434-007-9484-7
  49. Ikeguchi M, Oka S, Saito H, et al (1999). The expression of vascular endothelial growth factor and proliferative activity of cancer cells in gastric cancer. Langenbecks Arch Surg, 384, 264-70. https://doi.org/10.1007/s004230050202
  50. Itakura J, Kono K, Takahashi A, et al (2002). Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology, 62, 121-7. https://doi.org/10.1159/000048257
  51. Joensuu H, Mattson K, Ruotsalainen T, Salven P (1998). High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer, 79, 144-6. https://doi.org/10.1002/(SICI)1097-0215(19980417)79:2<144::AID-IJC8>3.0.CO;2-T
  52. Jons T, Juttner S, Wissmann C, et al (2006). Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol, 24, 228-40. https://doi.org/10.1097/00000658-200207000-00007
  53. Joo SY, Joo YE, Sohn YH, et al (2002). The role of vascular endothelial growth factor (VEGF) and p53 status for angiogenesis in gastric cancer. Korean J Intern Med, 17, 211-9. https://doi.org/10.1056/NEJMra0706596
  54. Kakeji Y, Koga T, Sumiyoshi Y, et al (2002). Clinical significance of vascular endothelial growth factor expression in gastric cancer. J Exp Clin Cancer Res, 21, 125-9. https://doi.org/10.4143/crt.2009.41.4.218
  55. Kang SM, Maeda K, Ogawa M, et al (1997). Combined analysis of vascular endothelial growth factor and platelet-derived endothelial cell growth factor expression in gastric carcinoma. Int J Cancer, 74, 545-50. https://doi.org/10.1002/(SICI)1097-0215(19971021)74:5<545::AID-IJC12>3.0.CO;2-5
  56. Kang SM, Maeda K, Onoda N, et al (1998). Expression of p53 and vascular endothelial growth factor associated with tumor angiogenesis and prognosis in gastric cancer. Oncology, 55, 594-9. https://doi.org/10.1159/000011918
  57. Kang SM, Maeda K, Onoda N, et al (1999). Vascular endothelial growth factor expression in preoperative biopsy specimens correlates with disease recurrence in patients with early gastric carcinoma. Cancer, 86, 566-71. https://doi.org/10.1002/(SICI)1097-0142(19990815)86:4<566::AID-CNCR4>3.0.CO;2-1
  58. Karayiannakis AJ, Polychronidis A, Syrigos KN, et al (2002). Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg, 236, 37-42. https://doi.org/10.1097/00000658-200207000-00007
  59. Kerbel RS (2008). Tumor angiogenesis. N Engl J Med, 358, 2039-49. https://doi.org/10.1056/NEJMra0706596
  60. Kim JG, Lee SJ, Sohn SK, et al (2009). No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer. Cancer Res Treat, 41, 218-23. https://doi.org/10.4143/crt.2009.41.4.218
  61. Kim JG, Lee SJ, Sohn SK, et al (2009). No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer. Cancer Res Treat, 41, 218-23. https://doi.org/10.4143/crt.2009.41.4.218
  62. Kimura H, Konishi K, Nukui T, et al (2001). Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma. J Surg Oncol, 76, 31-6. https://doi.org/10.1002/1096-9098(200101)76:1<31::AID-JSO1006>3.0.CO;2-9
  63. Kitadai Y, Takahashi R, Tanaka S, et al (2003). Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology, 64, 266-74. https://doi.org/10.1159/000069316
  64. Kobayashi O, Tsuburaya A, Yoshikawa T, et al (2000). Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett, 153, 7-12. https://doi.org/10.1016/S0304-3835(99)00426-7
  65. Kondo A, Saito H, Tsujitani S, et al (1999). Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma. Surgery, 125, 195-201. https://doi.org/10.1016/S0039-6060(99)70265-5
  66. Kondo S, Toi M, Yamamoto Y, et al (1996). Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res, 2, 821-6. https://doi.org/10.3748/wjg.14.2691
  67. Kraft A, Ochs A, Weindel K, et al (1999). Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer, 85, 178-87. https://doi.org/10.1002/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7
  68. Kuwano H, Shimura T, Tsutsumi S, et al (2005). Vascular endothelial growth factor C (VEGF-C) expression in pT2 gastric cancer. Hepatogastroenterology, 52, 629-32. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  69. Lau C, Ng IO, Poon RT, et al (2001). Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg, 233, 227-35. https://doi.org/10.1097/00000658-200102000-00012
  70. Li G, Wu J, Zhou Y, et al (2010). Clinicopathological significance of E-cadherin, VEGF, and MMPs in gastric cancer. Tumour Biol, 31, 549-58. https://doi.org/10.1007/s13277-010-0068-y
  71. Lv XJ, Wang J, Zhan P, et al (2009). Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol, 4, 1094-103. https://doi.org/10.1097/JTO.0b013e3181a97e31
  72. Ma J, Ru GQ, Zhang L, Zhao ZS (2006). Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer. World J Gastroenterol, 12, 3970-6.
  73. Masselou K, Papastratis G, Tsirlis TD, et al (2008). Circulating lymphangiogenic growth factors in gastrointestinal solid tumors, could they be of any clinical significance. World J Gastroenterol, 14, 2691-701. https://doi.org/10.3748/wjg.14.2691
  74. Park JM, Park KH, Seo HY, et al (2010). Prognostic significance of serum vascular endothelial growth factor per platelet count in unresectable advanced gastric cancer patients. Jpn J Clin Oncol, 40, 1147-53. https://doi.org/10.1093/jjco/hyq111
  75. Parmar MK, Stewart L, Torri V (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  76. Pera M, Soriano-Izquierdo A, Vidal O, et al (2008). Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg, 12, 1005-14. https://doi.org/10.1007/s11605-007-0336-3
  77. Wang J, Yang S, Zhang H, et al (2011). Aurora-A as an independent molecular prognostic marker in gastric cancer. Oncol Rep, 26, 23-32.
  78. Yang Q, Ye ZY, Zhang JX, et al (2010). Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Anat Rec (Hoboken), 293, 2012-9. https://doi.org/10.1002/ar.21071

Cited by

  1. Hypoxia-inducible Factor 1 Alpha (HIF-1α) as a Prognostic Indicator in Patients with Gastric Tumors: A Meta-analysis vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4195
  2. Prognostic value of HIF-1α expression in patients with gastric cancer vol.40, pp.11, 2013, https://doi.org/10.1007/s11033-013-2715-z
  3. The VEGF pathway in lung cancer vol.72, pp.6, 2013, https://doi.org/10.1007/s00280-013-2298-3
  4. CD44v3 and VEGF-C Expression and its Relationship with Lymph Node Metastasis in Squamous Cell Carcinomas of the Uterine Cervix vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.5049
  5. Molecular targeting to treat gastric cancer vol.20, pp.38, 2014, https://doi.org/10.3748/wjg.v20.i38.13741
  6. Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis vol.35, pp.3, 2014, https://doi.org/10.1007/s13277-014-1692-8
  7. DNA methylation regulates expression of VEGF-C, and S-adenosylmethionine is effective for VEGF-C methylation and for inhibiting cancer growth vol.47, pp.12, 2014, https://doi.org/10.1590/1414-431X20144005
  8. Emerging kinase inhibitors of the treatment of gastric cancer vol.20, pp.3, 2015, https://doi.org/10.1517/14728214.2015.1051467
  9. Angiogenesis inhibitors in early development for gastric cancer vol.26, pp.9, 2017, https://doi.org/10.1080/13543784.2017.1361926
  10. New drug developments in metastatic gastric cancer vol.11, pp.1756-2848, 2018, https://doi.org/10.1177/1756284818808072